Navigation Links
Cerecor Acquires Rights to NR2B Receptor Antagonist from Merck
Date:4/19/2013

BALTIMORE, April 19, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

There is a growing body of evidence to support the hypothesis that NMDA receptors are involved in the pathology of depression, including reports in the literature of rapid improvement of depression following intravenous administration of ketamine, an NMDA antagonist. MK-0657 is a novel potent and selective NR2B antagonist, initially developed by Merck for the treatment of Parkinson's disease.

"MK-0657 is a potential first-in-class, best-in-class, oral medication that is complementary to existing treatments in depressed patients who have failed to respond to available therapies. We are particularly interested in the potential to rapidly reduce depressive symptoms, including suicidal ideation, in these severely affected patients," stated Dr. James Vornov , Cerecor's Sr. VP of Clinical Development and Regulatory Affairs.

Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of MK-0657.  License consideration includes milestone payments and royalties consistent with clinical stage licenses in neuroscience. Cerecor anticipates completing the technology transfer activities by mid-2013 and thereafter initiating clinical trials.

"We are delighted that Merck has chosen Cerecor to help realize the value of an innovative asset such as MK-0657," added Dr. Blake Paterson , Cerecor's co-founder and CEO. "Patients and families who have struggled with severe refractory depression and suicidality easily recognize the need for more effective treatments, and we will develop MK-0657 with the purpose that befits such an important unmet need."

"Merck is pleased to sign this agreement with Cerecor as part of its ongoing out-licensing strategy.  Cerecor has established scientific and clinical expertise in the area of treatment resistant depression, an area of significant unmet medical need," said Dr. David Michelson , Vice President of Clinical Neuroscience and Ophthalmology, Merck Research Laboratories.

About Cerecor

Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We focus on targets or technologies that have demonstrated human proof of concept, and for which biomarkers could be used to steer early clinical development.  We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder , Barbara Slusher , Blake Paterson and Mr. Isaac Blech .  Cerecor is focused on translational medicine – the accelerated transfer of technology from the laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.  www.cerecor.com

Media Contact:
Michelle Avery
MacDougall Biomedical Communications
781-235-3060


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerecor Acquires Rights to Merck COMT Inhibitors
2. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
3. Dr. Magnus Persson Joins Cerecors Board of Directors
4. Cerecor Announces Initiation of CLIN01-002-A
5. MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
6. Numotion Acquires Ultimate Mobility, Inc.
7. VWR International, LLC Acquires Basan UK Limited
8. Kimberly-Clark Health Care Acquires Anesthesia Business from Life-Tech
9. VWR International, LLC Acquires Prolab Laboratuar Teknolojileri Limited In Turkey
10. Oncologix Tech Inc. (OCLG) Acquires Dotolo; Gains Ongoing Sales, Patents, and New CEO
11. Kimberly-Clark Heath Care Acquires Anesthesia Business from Life-Tech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Prefilled Syringes Market: Scope and Segmentation ... This report provides a forecast and analysis of ... regional levels. It provides historical data of 2015 ... terms of revenue (US$ Mn) and volume (Bn ... with an outlook on prefilled syringes consumption globally. ...
(Date:2/28/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Read ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... , Feb. 28, 2017 Summary ... This report provides all ... its partnering interests and activities since 2010. Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... The Industrial Designers Society of America (IDSA) is ... of the profession of industrial design (ID) and relaunching "What Is ID?" β€”one ... students and counselors; parents; and the greater public. , Share details and photos of ...
(Date:3/1/2017)... (PRWEB) , ... March 01, ... ... Association (ACMA) is pleased to announce the release of its 2017 update ... for case management staff and physician advisors. , Suitable for standardizing both ...
(Date:3/1/2017)... ... March 01, 2017 , ... Grund® America is proud to ... launching at the March 2017 International Housewares Show in Chicago (Grund Booth N6466). , ... with the highest quality,100% OEKO-TEX and GOTS Organic Cotton material. By adding the ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite Peaks Gastroenterology recently announced ... by supporting the 80% by 2018 initiative, led by the American Cancer Society ... Cancer Roundtable (an organization co-founded by ACS and CDC). , β€œ80% by 2018” ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... has announced special pricing in the month of March for treatments aimed at ... ” special features use on Thermage skin tightening, with 30 percent off all ...
Breaking Medicine News(10 mins):